['hodgkin lymphoma']
['brentuximab vedotin', 'nivolumab']

        Inclusion Criteria:

          -  Relapsed or refractory Hodgkin lymphoma following failure of standard frontline
             chemotherapy for the treatment of classical Hodgkin lymphoma

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

        Exclusion Criteria:

          -  Previously treated with brentuximab vedotin, immune-oncology agents, or received an
             allogeneic or autologous stem cell transplant

          -  Documented history of a cerebral vascular event

          -  History of another invasive malignancy that has not been in remission for at least 3
             years

          -  History of progressive multifocal leukoencephalopathy (PML)
      